Breast cancer is the 4th most common cause of cancer death in women in the UK, with around 11,500 breast cancer deaths in the UK every year. There is a good chance of recovery if it's detected at an early stage. If an immediate female family relative (mother, sister or daughter) is diagnosed with breast cancer then your risk doubles of developing breast cancer. This risk is even higher when more close relatives have breast cancer, or if a relative developed breast cancer under the age of 50.
Some types of ovarian cancer are more likely to have a genetic cause than others. It is also a cancer that is often diagnosed late as symptoms only develop late. Our Hereditary Breast & Gynaecological Cancer Panel screens the genes most commonly linked with genetic breast & gynaecological cancers. The aim of screening these genes is to detect your risk of developing these cancers, get access to screening programmes and potentially catch a cancer in its early stages when it is still confined and potentially curable.
The panel has been designed based on solid clinical evidence, ensuring that the genes tested can provide meaningful, actionable results. Only high impact clinically actionable risk variants are reported.
Your final report will provide genetic variant interpretation, the implications of the results, and any recommended actions. Full genetic counselling is available for you if a variant is detected to explain test results, the associated implications, identification of risk management and screening programmes, and to provide you with relevant support networks, thus reducing the risk of developing the associated cancer and aid in early cancer detection.
BREAST & GYNAECOLOGICAL CANCER PANEL
ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK22, EPCAM, MLH1, MSH2, MSH6, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
MARCH SPECIAL OFFER - £50 OFF THE TEST - WAS £499, NOW ONLY £449 in support of Ovarian Cancer Awareness Month
"In the last decade we’ve seen some major milestones – three Olympics, five Prime Ministers, and more superhero movies than we can count, but one-year ovarian cancer survival rates have stood still." - Ovarian.org.uk
Our aim therefore this month is to get as many women as possible to identify whether they are carrying a variant in their DNA which could increase your risk of developing ovarian cancer. Early access to screening programs leads to early diagnosis and a better outcome!
Our hereditary cancer panels analyse your DNA, extracted from cells in your saliva. With the panels specifically designed to provide results that are clinically approved and based on solid clinical evidence you can take the test from the comfort of your own environment, get your results delivered to you directly and gain access to screening programmes quickly, where appropriate.
Order online and we will send you a saliva sampling kit. It contains everything you need including links to a pre-test counselling video and consent form.
Return the sample in the pre-paid Tracked 48 packaging.
DNA extracted, sequenced, analysed and reported within 15-20 working days.
If a variant of concern is detected we will notify you and arrange an appointment with a Genetic Counsellor.
Your kit will include easy to follow instructions for use plus the following items:
A) Saliva collection device
B) Protective Pouch
C) Pack Contents/Instructions For Use card
D) Hereditary Cancer Panel Consent Form
E) Tamperproof sticker
F) Postage prepaid return box
There are two possible outcomes. Positive or Negative. In the case of a positive report it will provide genetic variant interpretation, the implications of the results, and any recommended actions.
If a pathogenic or likely-pathogenic, clinically significant, variant is detected it is important to remember that this does not mean you will definitely get cancer. This is a predictive genetic test associated only with the risk of developing cancer, enabling you to make proactive lifestyle choices if you wish, and gain access to possible screening programmes. For more information on the reporting please see our FAQs. This service is available to anyone over 18 years of age who is believed to be at risk of developing cancer, regardless of personal or familial cancer history.
